Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M24,701Revenue $M1,212Net Margin (%)-56.9Z-Score12.2
Enterprise Value $M24,000EPS $-2.0Operating Margin %-97.1F-Score2
P/E(ttm))0Cash Flow Per Share $-0.3Pre-tax Margin (%)-103.7Higher ROA y-yN
Price/Book20.210-y EBITDA Growth Rate %0Quick Ratio3.7Cash flow > EarningsY
Price/Sales29.15-y EBITDA Growth Rate %0Current Ratio3.7Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-20.0Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-37.2Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M236ROI % (ttm)-31.5Gross Margin Increase y-yY

Gurus Latest Trades with VRTX

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VRTXJohn Burbank 2014-06-30 Sold Out -0.01%$62.44 - $93.77
($69.73)
$ 100.3744%Sold Out0
VRTXGeorge Soros 2014-06-30 Sold Out -0.01%$62.44 - $93.77
($69.73)
$ 100.3744%Sold Out0
VRTXVanguard Health Care Fund 2014-03-31 Add0.13%$67.8 - $85.48
($79.08)
$ 100.3727%Add 5.89%11,628,500
VRTXGeorge Soros 2014-03-31 Buy 0.01%$67.8 - $85.48
($79.17)
$ 100.3727%New holding, 10000 sh.10,000
VRTXJohn Burbank 2014-03-31 Buy 0.01%$67.8 - $85.48
($79.17)
$ 100.3727%New holding, 2872 sh.2,872
VRTXVanguard Health Care Fund 2013-12-31 Add0.88%$60.18 - $77.83
($69.45)
$ 100.3744%Add 54.06%10,981,500
VRTXVanguard Health Care Fund 2013-09-30 Add0.29%$74.53 - $88.51
($79.62)
$ 100.3726%Add 19%7,127,997
VRTXVanguard Health Care Fund 2013-06-30 Add1.05%$52.6 - $85.6
($73.64)
$ 100.3736%Add 140.58%5,990,000
VRTXDaniel Loeb 2012-12-31 Sold Out -0.77%$38.88 - $59.42
($46.08)
$ 100.37118%Sold Out0
VRTXJohn Burbank 2012-12-31 Sold Out -0.38%$38.88 - $59.42
($46.08)
$ 100.37118%Sold Out0
VRTXDaniel Loeb 2012-09-30 Add0.22%$48.38 - $59.07
($53.5)
$ 100.3788%Add 40%700,000
VRTXJohn Burbank 2012-09-30 Reduce-0.09%$48.38 - $59.07
($53.5)
$ 100.3788%Reduce -25%150,000
VRTXGeorge Soros 2012-09-30 Sold Out -0.09%$48.38 - $59.07
($53.5)
$ 100.3788%Sold Out0
VRTXJoel Greenblatt 2012-09-30 Sold Out -0.08%$48.38 - $59.07
($53.5)
$ 100.3788%Sold Out0
VRTXDaniel Loeb 2012-06-30 Buy 0.85%$35.75 - $65.62
($50.92)
$ 100.3797%New holding, 500000 sh.500,000
VRTXJohn Burbank 2012-06-30 Buy 0.38%$35.75 - $65.62
($50.92)
$ 100.3797%New holding, 200000 sh.200,000
VRTXJoel Greenblatt 2012-06-30 Buy 0.08%$35.75 - $65.62
($50.92)
$ 100.3797%New holding, 20025 sh.20,025
VRTXJohn Hussman 2012-06-30 Sold Out -0.93%$35.75 - $65.62
($50.92)
$ 100.3797%Sold Out0
VRTXGeorge Soros 2012-06-30 Reduce-0.05%$35.75 - $65.62
($50.92)
$ 100.3797%Reduce -44%112,000
VRTXJean-Marie Eveillard 2012-06-30 Sold Out -0.02%$35.75 - $65.62
($50.92)
$ 100.3797%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VRTX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
VRTX Vanguard Health Care Fund 2014-06-3011,807,50052.9+1.54%
VRTX John Burbank 2014-06-30000Sold Out
VRTX George Soros 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


VRTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BOGER JOSHUA SDirector 2014-09-17Sell5,200$93.627.21view
BOGER JOSHUA SDirector 2014-09-10Sell5,200$94.426.3view
ALTSHULER DAVIDDirector 2014-09-05Sell2,500$94.755.93view
BOGER JOSHUA SDirector 2014-09-03Sell5,200$92.798.17view
BOGER JOSHUA SDirector 2014-08-27Sell5,200$93.317.57view
BOGER JOSHUA SDirector 2014-08-20Sell5,200$91.519.68view
BOGER JOSHUA SDirector 2014-08-13Sell5,200$8814.06view
BOGER JOSHUA SDirector 2014-08-06Sell5,200$86.5415.98view
ALTSHULER DAVIDDirector 2014-07-31Sell5,000$89.5912.03view
Silva Paul MSVP & Corp Controller 2014-07-31Sell2,027$88.9712.81view

Press Releases about VRTX :

    Quarterly/Annual Reports about VRTX:

    News about VRTX:

    Articles On GuruFocus.com
    Vanguard Health Care Fund Buys Vertex Pharmaceuticals, Zoetis Inc, , Sells Cerner Corporation, AbbVi Aug 02 2013 
    Weekly Guru Bargains Highlights: MBI, VRTX, GRPN, PBI, PC Dec 16 2012 
    WEEKLY CFO SELLS HIGHLIGHT: AKRX, FIO, OVRL, VRTX Oct 21 2012 
    Idenix Pharmaceuticals Lagging Behind in Breakthrough Hepatitis C Drug Development Jul 13 2012 
    Weekly Top Insider Sells: GMCR, VRTX, CERN, and AGN May 14 2012 
    Vertex Could Climb On New Drug, VX-222 Success Apr 21 2012 
    Achillion Will Surge If New Drug Is Successful Apr 21 2012 
    Columbia Management Fourth Quarter Letter with Comments on SWK, AGCO, CE, MCP, VRTX, DOLE, F, HAS, A Apr 10 2012 
    Was Gilead's Acquisition of Pharmasset a Dose of Bad Medicine? Mar 05 2012 
    4 Pharmaceuticals with Long and Short Opportunities Feb 28 2012 


    More From Other Websites
    Today's Market Thorns, Roses, and All Time Highs... Sep 19 2014
    US STOCKS-Biotech shares drop, Amarin plunges 20 pct Sep 12 2014
    US STOCKS-S&P 500 rebounds with energy shares; Dow dips Sep 11 2014
    US STOCKS-S&P 500 rebounds with energy shares; Dow dips Sep 11 2014
    Stocks close mixed ahead of data; geopolitics in backseat Sep 11 2014
    US STOCKS-Wall St down slightly, financials help limit losses Sep 11 2014
    US STOCKS-Wall St down slightly, financials help limit losses Sep 11 2014
    Vertex Announces Upcoming Presentations of Data at North American Cystic Fibrosis Conference -... Sep 08 2014
    Today's Thorns, Roses, and All Time Highs... Sep 05 2014
    Analysts' Actions: Ciena, Finisar, Vertex and More Sep 05 2014
    Vertex to Present at the Morgan Stanley Global Healthcare Conference on September 10 Sep 02 2014
    No, the Biotech Rally Isn't Over Sep 02 2014
    Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus Aug 20 2014
    SEC probing Valeant, Ackman's hostile Allergan bid - WSJ Aug 14 2014
    Vertex leads S&P 500, King drops on outlook Aug 13 2014
    Vertex to end sales of hepatitis C drug Incivek Aug 13 2014
    From Riches to Rags: Vertex Discontinues Incivek as Sales Evaporate Aug 12 2014
    GW Pharma, Insys Face Off In Cannabis Drug Space Aug 08 2014
    A Healthy Biotech ETF Aug 08 2014
    VERTEX PHARMACEUTICALS INC / MA Financials Aug 08 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK